Αποτελέσματα Αναζήτησης
Download Medicare Reimbursement Guide. If you have questions related to Cardiolite ® reimbursement, please call (800) 362-2668 (Option 3) or email reimbursement@lantheus.com. Lantheus cannot guarantee coverage or payment for products or procedures.
- Two Day Stress/Rest
Two Day Stress/Rest - Reimbursement - Cardiolite
- Risk Stratification
*Based on a prospective study of 5,807 consecutive patients,...
- Imaging Protocols
Imaging Protocols. Suggested Cardiolite ® One-Day...
- Prescribing Information
Prescribing Information - Reimbursement - Cardiolite
- Perfusion and Function
Myocardial Perfusion and Function assessed by a Gated...
- Patients
Patients - Reimbursement - Cardiolite
- Two Day Stress/Rest
CARDIOLITE® is a myocardial perfusion agent indicated for: detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects) evaluating myocardial function and developing information for use in patient management decisions.
CARDIOLITE® is a myocardial perfusion agent indicated for: • detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects)
25 Μαρ 2024 · Cardiolite package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.
Billing for the radiopharmaceutical agents: 1. Radiopharmaceuticals are available in unit dose or in bulk doses, the latter requiring preparation at the imaging center. Use of radiopharmaceuticals is regulated by the Nuclear Regulatory Commission (NRC) under strict procedures and guidelines.
19 Σεπ 2023 · Cardiolite is a beta blocker medication primarily used to treat high blood pressure and heart-associated chest pain. Atenolol, however, does not seem to improve mortality in those with high blood pressure.
Cardiolite ® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection) is one of the world’s foremost cardiac imaging agents. For nearly three decades, since the launch of the product in 1991, Cardiolite ® has played a vital role in the diagnosis and management of patients with known or suspected coronary artery disease.
